Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 29;8:13025. doi: 10.1038/s41598-018-31328-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Nexilin/NEXN expression is controlled by YAP and by myocardin family coactivators. Panel A shows phosphorylation of YAP (P-YAP) in human coronary artery SMCs (HCASMCs) prior to and at different times after addition of sphingosine-1-phosphate (S1P). Panel B shows compiled data on YAP phosphorylation (N = 9). In panel C, qRT-PCR for NEXN and CTGF at different times after S1P addition is shown (N = 9). Panel D shows NEXN mRNA expression following adenoviral transduction of YAP1 and S1P treatment, individually and in combination (N = 11). Panel E shows the effect of dual silencing of YAP(YAP1) and TAZ (WWTR1) on NEXN mRNA expression under basal conditions and after S1P stimulation of human bladder SMCs (HBSMCs) (N = 9). Panel F shows the mRNA level of NEXN after overexpression of MRTF-A/MKL1 and YAP1, alone and in combination (N = 9). Panel G shows the mRNA level of NEXN in control conditions and following overexpression of MRTF-A/MKL1, MRTF-B/MKL2 and myocardin/MYOCD (HBSMCs, N = 6–8; HCASMCs, N = 6). Panel H shows western blots for Nexilin following overexpression of MRTFs in bladder (top) and coronary artery (bottom) SMCs, and panel I shows compiled protein data (N = 9). Panel J shows the mRNA level for SRF following silencing of SRF, YAP/TAZ, or both. Panel K shows the associated reduction of the NEXN mRNA (N = 6). Panel L shows the effect of pharmacological inhibition of MRTF/SRF signaling in bladder and coronary artery SMCs (HBSMCs, N = 12; HCASMCs, N = 9).